FDA Approves Base Therapeutics' NK Cell Therapy with GenScript Support, Paving the Way for Advanced Cancer Treatments Base Therapeutics has secured FDA approval for its NK510 program utilizing GenScript's pioneering base editing technology, promising significant advancements in cancer therapies.

FDA Approves Base Therapeutics' NK Cell Therapy with GenScript Support, Paving the Way for Advanced Cancer Treatments #USA #GenScript #Piscataway #Base_Therapeutics #NK510